The Life Sciences team advised Tessera Therapeutics on its Series C financing, which totaled over $300 million.
Tessera is a biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology. The GENE WRITING platform can change any base pair to any other, make small insertions or deletions, and write entire genes into the genome with delivery of only RNA. This unlocks the potential to cure nearly any genetic disease, create life-changing medicines for other serious conditions such as cancer, and prevent illnesses with curative, scalable, and easily administered genetic medicines that could become a new modality in human healthcare.
Tessera was founded by Flagship Pioneering, a company that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in more than $200 billion in aggregate value.
The Goodwin team was led by Stuart Cable included Joseph Flynn and William Ogden with assistance from Steven Green (Corporate), Rich Matheny, Justin Pierce and Amy Josselyn (Global Trade), Mark Burnett (Opinions), and Dan Karelitz (Tax).
For more details, read the press release and articles in Endpoints and Bloomberg.